Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 40 of the 54 sources its claims cite were checked for support.
Abstract
Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to months. A notable recent discovery shows that ketamine, a N -methyl- d -aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants. Basic studies show that ketamine rapidly induces synaptogenesis and reverses the synaptic deficits caused by chronic stress. These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.
Overview
CoChat Summary
TL;DR
The paper proposes a synaptogenic hypothesis of depression: stress and depression cause synaptic loss and neuronal atrophy in mood-related circuits, while rapid-acting ketamine reverses these deficits through glutamate burst, BDNF, mTOR, and synaptogenesis. It contrasts slow typical antidepressants with ketamine and highlights new therapeutic targets.
Key findings
- Depression is associated with decreased volume of cortical and limbic regions such as the prefrontal cortex (PFC) and hippocampus, and postmortem studies report decreased synapse number in the dorsolateral PFC, reduced pyramidal neuron size but not number, decreased GABAergic interneurons and glia, and altered GABA/glutamate cycling.
- Chronic stress in rodents reduces apical dendrite length and branching and decreases spine synapse number and function in layer V pyramidal neurons of the medial PFC; atrophy is observed after as little as 1 week of restraint stress (20 to 30 min per day), and chronic stress also decreases adult hippocampal neurogenesis and medial PFC glia.
- Ketamine produces rapid antidepressant responses within hours in treatment-resistant depressed patients, with effects sustained for 7 to 10 days; in rodents it rapidly induces synaptogenesis, reverses spine density deficits and anhedonia/anxiety caused by 3 weeks of chronic stress, and requires mTOR signaling, BDNF, Arc, and GSK3 inhibition.
- Typical antidepressants such as SSRIs take weeks to months to produce therapeutic response and leave more than one-third of depressed individuals resistant; they increase neurotrophic factor expression and plasticity slowly, whereas ketamine more profoundly affects fast excitatory glutamate transmission, BDNF release, and synaptogenesis.
Methods
- Review/perspective article synthesizing basic and clinical literature; no new primary data are reported.
- Evidence reviewed includes human brain-imaging and postmortem MDD studies, rodent chronic stress models (e.g., chronic unpredictable stress, restraint stress), and pharmacological studies of typical antidepressants and ketamine.
- Narrative synthesis comparing mechanisms of typical antidepressants and ketamine and proposing a synaptogenic hypothesis; no systematic review or meta-analysis is described.
Limitations
- Stated in the paper: MDD neurobiology remains poorly understood due to lack of biomarkers, relatively low heritability, and heterogeneity of precipitating factors; imaging provides connectivity information but not the integrity and efficiency of connections; postmortem neuronal morphology studies are hampered by poor fixation and tissue condition; preclinical interpretation is limited by available animal models, and additional human imaging is needed to confirm ketamine circuitry.
- Stated in the paper: ketamine’s psychotomimetic effects and abuse potential limit its development and use; clinical response to NR2B selective agents does not appear as rapid as ketamine, and further studies are needed; many molecular alterations in depression cannot always be distinguished from medication status because studies are not always sufficiently powered.
- Evident from the text: as a review, it does not provide a systematic search strategy, quality assessment, or primary quantitative synthesis; many mechanistic conclusions rely on rodent models and correlational human postmortem/imaging findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 0 Not valid · 4 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies of neuronal morphology in human postmortem brain tissue have been hampered by poor fixation and tissue condition, but we recently reported that the number of synapses, determined by electron microscopy, is decreased in the dlPFC of depressed patients (16).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Neuronal Atrophy and Synaptic Loss in Depression
What the sources say
- Supportedcites [16] Kang HJ Nat. Med 2012 18 1413 22885997 PMC3491115 source
The paper reports a marked decrease in spine synapse number in the dorsolateral prefrontal cortex of subjects with major depressive disorder compared with controls. Its Electronic Microscopic Stereology methods describe counting those synapses in postmortem tissue using electron micrographs. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
- Also stated in: § Abstract · boosted
“Recent studies report what is arguably the most important discovery in half a century: the therapeutic agent ketamine that produces rapid (within hours) antidepressant actions in treatment-resistant depressed patients (4, 5).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] Berman RM Biol. Psychiatry 2000 47 351 10686270 source
- Supportedcites [5] Zarate CA Jr Arch. Gen. Psychiatry 2006 63 856 16894061 source
The Comment section reports a robust antidepressant response to ketamine within hours in treatment-resistant subjects, with improvement over placebo significant from 110 minutes on clinician ratings and 40 minutes on self-ratings. It also identifies ketamine as an NMDA antagonist. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“Chronic unpredictable stress (CUS), a putative model of depression, results in behavioral abnormalities, including core symptoms of depression such as anhedonia (7).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Stress Causes Neuronal Atrophy and Decreases Synaptic Density
What the sources say
- Supportedcites [7] Li N Biol. Psychol 2011 69 754 source
The Conclusions describe CUS as a paradigm that results in anhedonia, a core symptom of depression. The Results report that CUS-exposed rats showed reduced sucrose preference, indicating anhedonia, and increased latency to feed in a novel environment, indicating another behavioral abnormality. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Partly supportedcites [6] Li N Science 2010 329 959 20724638 PMC3116441 sourceExperimental — accuracy not yet measured
The passage on behavioral tests (labeled Abstract; Fig. 3D–F) reports that local rapamycin infusion into the medial PFC completely blocked ketamine’s effects in the forced swim and novelty-suppressed feeding tests. Our copy does not report a dorsal-striatum infusion or establish that it failed to block those effects, so the regional comparison is unsupported. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the synaptogenic actions of ketamine are blocked in mice with a knock-in of the BDNF Met allele that impairs BDNF mRNA transport to dendrites, as well as in conditional BDNF mutant mice (32, 49).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Not matchedcites [32] Liu R Biol. Psychol 2012 71 996
Its entry has no title and year that we can search by.
- Partly supportedcites [49] Autry AE Nature 2011 475 91 21677641 PMC3172695 sourceExperimental — accuracy not yet measured
The Abstract (page not provided) reports that ketamine did not produce antidepressant-like behavioural effects in inducible BDNF knockout mice. It does not report that ketamine’s synaptogenic effects were blocked in those mice, or describe BDNF Met knock-in mice or impaired dendritic mRNA transport. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Not matched
14 more claims · 10 with their cited sources checked
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While synaptic plasticity is a well-known key mechanism in learning and memory (Dayan and Cohen, 2011;Kandel, 2001), unequivocal studies suggest that dysfunction of synaptic plasticity with neuronal atrophy and cell death contribute to the pathophysiology of depression and therapeutic response could be associated with overcoming this deficit (Duman and Aghajanian, 2012;Krystal et al., 2013;Shakesb”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, synaptic dysfunctions with neuronal atrophy and reductions of glial and GABAergic interneurons in the dorsolateral prefrontal cortex (dlPFC) are found in post-mortem analyses of brains of depressive patients (and animal models of chronic unpredictable stress; Duman and Aghajanian, 2012; Underwood et al., 2012).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Broadly, positive valence system deficits are linked primarily to altered dopaminergic and/or opioid signaling within midbrain striatal circuits 94,101 , but may intersect with plasticity impairments and dysconnectivity of excitatory glutamatergic synapses in an overlapping prefrontal-mesolimbic circuit 5 to produce the full spectrum of affective biases seen in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such complex effects seem to ultimately result in increased neurogenesis and synaptogenesis, improved neuroplasticity, and normalization of stress-related neurodegeneration [77,78].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postmortem findings from these animal models consistently demostrate that stress induces synaptic dysfunction [5,6,135], including reductions in synaptic density, as measured by both quantification of synaptic structure and assessments of synaptic protein expression”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Research works printed but not linked: 3
- Collinridge GL Peineau S Howland JG Wang YT Nat. Rev. Neurosci 2010 11 459 20559335
- 10.1016/0306-4522(95)00259-L · DOI · Paper page
- Machado-Vieira R Ibrahim L Henter ID Zarate CA Jr Pharmacol. Biochem. Behav 2012 100 678 21971560 PMC3253881 · DOI · Paper page
Cited by
Items 1,101–1,200 of 1,640
Li, F., Wang, G., Genon, S., Eickhoff, S. B., He, R., Yi, C., Dong, D., Yao, D., Jiang, L., Wu, W., et al. (2025) · Science Advances · doi:10.1126/sciadv.adz0389 · Cited by 7
Han, M., Xie, B., Yuan, Y., Xu, D., Shi, Y., Xu, M., Wu, Y., Zhang, Y., Wen, X., Wang, X., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03656-4 · Cited by 10
“Given that depression is associated with synaptic dysfunction [35, 36], we quantified the expression of synaptic proteins synaptophysin (SYN) and postsynaptic density protein 95 (PSD-95) in the hippocampus, a key region of depression [37].”
Psychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model
Kandilakis, C. L., & Papatheodoropoulos, C. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00892 · Cited by 5
“4,124 At the receptor level, psilocybin reduces hippocampal 5-HT 1A receptor protein expression at both low and high doses, while exerting dose-specific effects on 5-HT 2A receptor density (decreasing it at low dose, increasing at high dose).”
Cheung, N. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261433953 · Cited by 4
“12,23 Because BDNF/tropomyosin receptor kinase B (TrkB) signaling falters early in AD, repeated activation through the Cheung stack could hold synaptic density steady in people at risk.”
Dai, S., Luo, M., Jiang, T., Lu, M., Zhou, X., Zhu, S., Han, X., Yang, F., Wang, H., & Xu, D. (2024) · Environment International · doi:10.1016/j.envint.2024.109064 · Cited by 7
Chu, C.-C., Hu, Y.-H., Li, G.-Z., Chen, J., Zhang, N.-N., Gu, Y., Wu, S., Zhang, H., Xu, Y.-Y., Guo, H.-L., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106812 · Cited by 4
Wu, D., Qu, S., Sun, H., Zhou, S., Qu, X., Chen, Y., Hu, H., & Li, X. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111246 · Cited by 5
“…most cited documents emphasizes the critical role of homeostatic control of emotional circuit connectivity in the behavior of depression and the response to treatment, forming the basis of a synaptogenesis hypothesis regarding depression and the response to treatment (Duman and Aghajanian, 2012).”
Yang, L., Zhang, M., Sun, X., Du, A.-Q., Jia, J., Li, N., Hu, G., Lu, Y., Wang, S., Zhang, J., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-07802-9 · Cited by 4
“The Methods should also specify how double-labelled cells were determined, especially given that the staining for CamKII appears quite diffuse.”
LSD: Mechanisms and relevance to the treatment of depression
Bouloufa, A., Delcourte, S., Delannay, T., Rovera, R., Lau, T., Moulédous, L., Dkhissi‐Benyahya, O., Guiard, B. P., & Haddjeri, N. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106407 · Cited by 5
Thangaleela, S., Varman, D. R., Sivasangari, K., & Rajan, K. E. (2020) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2020.108873 · Cited by 6
Ribosomal DNA and Neurological Disorders
Zhou, H., Xia, Y., Zhu, R., Zhang, Y., Zhang, X., Zhang, Y., & Wang, J. (2024) · Current Molecular Medicine · doi:10.2174/0115665240292079240513093708 · Cited by 4
Zhu, W., Chang, J., Tian, L., Yang, X., & Li, W. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70394 · Cited by 6
Lueke, K., Kaiser, T., Svetlitchny, A., Welzel, O., Wenzel, E. M., Tyagarajan, S. K., Kornhuber, J., & Groemer, T. W. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1087-9 · Cited by 4
“This is in accordance with the ‘synaptogenic hypothesis’ that was recently proposed as a model for depression (Duman and Aghajanian 2012).”
ResultMicroglial Gene Expression Alterations in the Brains of Patients with Psychiatric Disorders
Sakai, M., Takahashi, Y., Yu, Z., & Tomita, H. (2016) · Advances in Neuroimmune Biology · doi:10.3233/nib-160110 · Cited by 5
Ketamine’s Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies
Averill, L. A., Murrough, J. W., & Abdallah, C. G. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_7 · Cited by 6
Dutar, P., Tolle, V., Kervern, M., Carcenac, C., Carola, V., Gross, C. T., Savasta, M., Darmon, M. C., & Masson, J. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.11.022 · Cited by 4
Абрамец, И. И., Зайка, Т. О., Евдокимов, Д. В., Kuznetsov, Y. V., & Sidorova, Y. V. (2020) · Pharmacokinetics and Pharmacodynamics · doi:10.37489/2587-7836-2020-1-18-24 · Cited by 4
Mohammadi‐Yeganeh, S., Bilanicz, S., & Dabbagh, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-53525-4_2 · Cited by 8
An Overview of Machine Learning Applications in Mood Disorders
Topolski, N., Jeong, S. H., & Mwangi, B. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.017 · Cited by 4
The Sustained Antidepressant Effects of Ketamine Are Independent of the Lateral Habenula
Zhou, X., Zhang, C., Miao, J., Chen, Z., Dong, H., & Liu, C. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.2521-20.2021 · Cited by 4
RetractedAlbott, C. S., Lee, S., Cullen, K. R., THURAS, P. D., Lissek, S. M., Wels, J., Friedrich, K. J., Krueger, A. M., & Lim, K. O. (2021) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20210012 · Cited by 4
Hwang, Y. H., Lee, M., Yun, C., Kim, Y., Baek, H., Han, B. S., & Kim, D. Y. (2021) · Journal of Spectroscopy · doi:10.1155/2021/6533727 · Cited by 4
Ortiz, D. M., Kim, M., Lee, H. J., Botanas, C. J., Custodio, R. J. P., Sayson, L. V., Campomayor, N. B., Lee, C., Lee, Y. S., Cheong, J. H., et al. (2023) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2022.159 · Cited by 6
“Patients with depression have been observed to show decreased BDNF levels (Duman and Aghajanian, 2012; Lang and Borg-wardt, 2013).”
High throughput assay for compounds that boost BDNF expression in neurons
Liao, G., Xu, H., Shumate, J., Scampavia, L. D., Spicer, T., & Xu, B. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.02.005 · Cited by 4
Mitsi, V., Ruiz, A., Polizu, C., Farzinpour, Z., Ramakrishnan, A., Serafini, R. A., Parise, E. M., Floodstrand, M., Sial, O. K., Gaspari, S., et al. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.123.000753 · Cited by 6
Miranda-Riestra, A., Cercós, M. G., Trueta, C., Oikawa‐Sala, J., Argueta, J., Constantino-Jonapa, L. A., Cruz‐Garduño, R., Benítez‐King, G., & Estrada‐Reyes, R. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.124.000890 · Cited by 5
Lento, R. M., & Boland, H. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-30687-8_11 · Cited by 6
Gene expression in peripheral blood in treatment-free major depression
Barboza, A. B. C., Sánchez-Ruiz, J. A., Rodriguez-Sanchez, I. P., González, S., Calvo‐Anguiano, G., Lugo-Trampe, J. D. J., Costilla-Esquivel, A., Martínez, L. E., & Ibarra‐Ramírez, M. (2020) · Acta Neuropsychiatrica · doi:10.1017/neu.2020.5 · Cited by 4
“Another important hypothesis is that of synaptic plasticity disruption, supported by research suggesting that alterations of the mechanisms in charge of synaptic plasticity maintenance and control result in a destabilisation of cerebral networks related to mood and emotions (Duman and Aghajanian, 2012).”
BackgroundIshiguro, M., Okada, A. K., Asai, K., Kojima, K., & Okada, H. (2015) · Microbiology and Immunology · doi:10.1111/1348-0421.12346 · Cited by 4
(2016) · Neurotransmitter · doi:10.14800/nt.1293 · Cited by 4
“Interestingly, the size and the number of synapses at several areas, including amygdala, nucleus accumbens, hippocampus, prefrontal cortex, and cingulate cortex, are reduced in animal models of depression and in depressed patients [24–26] .”
BackgroundWang, M., Li, P., da Silva, B. S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2007735/v1 · Cited by 4
Epigenetic regulation of BDNF-TrkB signaling in the pathophysiology and treatment of mood disorders
Boulle, F. (2013) · Research Publications (Maastricht University) · doi:10.26481/dis.20131129fb · Cited by 8
Liu, X., Niu, J., Liao, W., & Du, L. (2025) · Psychological Medicine · doi:10.1017/s0033291725000868 · Cited by 5
“…neurons through electrical stimulation, leading to wide-spread neural discharge and seizure-like activity, which in turn promotes the expression of genes related to neural plasticity, enhances synaptogenesis and neuronal connectivity, resulting in an increase in GMV (Duman & Aghajanian, 2012).”
Riggs, L. M., Aronson, S., Mou, T.-C. M., Pereira, E. F. R., Thompson, S. M., & Gould, T. D. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115743 · Cited by 4
Chen, D., Li, Q., Xiao, Y., Guo, Y., Jing, W., Che, K., Dong, F., Ma, H., Zhao, F., Lian, H., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119697 · Cited by 3
Yao, C., Xiao, Y., Wang, P., Zheng, Y., Sun, J., Wang, J., & Xue, S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119985 · Cited by 4
Guglielmo, R., Marino, M., Briasco, E., Cavanna, E., Inuggi, A., Schiavon, F., Giacomini, G., Malagamba, D., Escelsior, A., Martinotti, G., et al. (2025) · CNS Drugs · doi:10.1007/s40263-025-01210-7 · Cited by 4
“…between prior ADTs and treatment response may reflect greater treatment resistance, as seen in chronic depression and repeated pharmacological failures, where synaptic dysfunction, impaired glutamatergic signaling, and reduced neuroplasticity may limit esketamine’s therapeutic effects [10].”
Deficiency of Kif15 impairing synaptic development leads to mood disorder in mice
He, X., Zhang, W., Chen, X., Dong, Z., Wei, C., Wu, T., Kong, D., Kong, R., Wu, R., Liu, Y., et al. (2025) · PLoS Genetics · doi:10.1371/journal.pgen.1011839 · Cited by 5
“A large number of studies have shown that both depression and bipolar disorder are associated with abnormal synaptic function [23,24].”
Zhang, H., Huang, N., Ma, X., & Liu, Y. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07397-9 · Cited by 4
“PANoptosis is an inflammatory programmed cell death pathway regulated by the PANoptosome, which highlights the crosstalk and coordination between pyropto-sis, apoptosis, and necroptosis [10–12].”
Managing Chronic Pain: The Ketamine Option
Pickering, G. P., Morel, V., & Voute, M. (2025) · CNS Drugs · doi:10.1007/s40263-025-01234-z · Cited by 3
“Ketamine’s established rapid direct action on mood via NMDA receptor antagonism and subsequent AMPA receptor activation, leading to enhanced synaptic plasticity, is well-documented [142, 143].”
Anderson, T. L., Asadipooya, A., & Ortinski, P. I. (2025) · eNeuro · doi:10.1523/eneuro.0047-25.2025 · Cited by 4
“Similarly, disease states such as depression or substance use disorder that are known to involve serotonergic dysfunction can disrupt synaptic plasticity (Luscher and Malenka, 2011; Duman and Aghajanian, 2012; Appelbaum et al., 2023).”
Campolina, A. G., & de Oliveira, M. A. T. (2025) · Healthcare · doi:10.3390/healthcare13212714 · Cited by 5
Rominto, A. M., Montarolo, F., Berrino, L., Loddo, M., Bertolotto, A., Tempia, F., & Hoxha, E. (2025) · Scientific Reports · doi:10.1038/s41598-025-22321-7 · Cited by 4
“…some studies found alterations in synaptic transmission on mPFC pyramidal neurons, consisting in a depression of excitatory synapses with a reduction of dendritic branches and spines 18–20 and of postsynaptic AMPA and NMDA receptors 19 , which are rescued by treatment with antidepressant drugs 21 .”
Zhang, L., Wei, T., Liu, X., Luo, Y., Zhang, L., He, Y., Wu, R., He, Z., & Zeng, F. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120684 · Cited by 5
Differentiation of Therapeutic and Illicit Drug Use via Metabolite Profiling
Stoeva, S., Hvarchanova, N., Gancheva, S., Eftimov, M., Georgiev, K., & Radeva-Ilieva, M. P. (2025) · Metabolites · doi:10.3390/metabo15110745 · Cited by 7
Ping, L., Sun, D., Sun, S., He, M., Zhou, C., Chu, Z., Shen, Z., Xu, X., Chen, X., Yan, C., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03715-7 · Cited by 5
“Notably, the ‘ synaptic signaling ’ pathway, previously correlated with morphometric similarity network [43] and multimodal covariance network [62], was implicated in synaptic stability and maturation [73], playing critical roles in the pathology of depression[72].”
Chen, K., Li, Y., Wang, Y., Ge, J., Song, D., Li, Y., Yang, Q., Zhang, X., Qu, J., Shen, C., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117590 · Cited by 3
Role of Genetic and Epigenetic Biomarkers in Treatment-Resistant Depression: A Literature Review
Sulić, P., Pavičić, A. R., Ivančić, B. Đ., Božina, T., Božina, N., & Živković, M. (2025) · Genes · doi:10.3390/genes16121443 · Cited by 9
“Impairment of neuroplasticity in depression manifests as reduced synaptogenesis, dendritic atrophy, and impaired neurogenesis in regions such as the hippocampus and prefrontal cortex, contributing to emotional dysregulation and cognitive dysfunction [29,30].”
InfluentialChe, L., Xie, J., Xia, C., & Yu, Q. (2026) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s579710 · Cited by 3
Ketamine as a Bridge Therapy: Reducing Acute Suicidality in Hospital Settings
Lie, P. E., Lie, T., Nguyen, M., & Lie, D. Y. C. (2026) · Healthcare · doi:10.3390/healthcare14050634 · Cited by 3
“While the mechanism behind SSRI antidepressant activity is not yet fully elucidated, it is thought that BDNF plays a significant role in increasing synaptic plasticity and inducing the remodeling of actin filaments in the dendritic post-synaptic spines [7].”
Srivastava, J., Yadav, J., & Dubey, N. (2026) · Cognitive Neurodynamics · doi:10.1007/s11571-026-10446-y · Cited by 3
Sun, Y., Zhao, D., Song, Q., Cong, T., Li, L., Wu, H., & Xiao, Z. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.06.004 · Cited by 3
Neuronal synaptic architecture revealed by cryo-correlative light and electron microscopy
Wang, P., Tian, B., Xu, X., Luan, H., Zhang, Y., Sun, W., Hu, L., Li, Y., Yao, Y., Li, W., et al. (2024) · Biophysics Reports · doi:10.52601/bpr.2024.240035 · Cited by 4
“…neurodevelopmental and neuropsychiatric disorders, such as Alzheimer’s disease (Blanco-Suárez et al. 2017; Peng et al. 2022; Scheff et al. 2015), schizophrenia (Blanco-Suárez et al. 2017; Yin et al. 2012), depression (Duman and Aghajanian 2012; Duman et al. 2016) and autism (Spooren et al. 2012).”
Edlund, E., Domarecka, E., Olze, H., & Szczepek, A. J. (2025) · Brain Sciences · doi:10.3390/brainsci15020110 · Cited by 4
“Alterations in synaptic AMPAR levels contribute to stress’s adaptive and maladaptive effects on neuroplasticity, which is essential for processes such as memory, learning, and cognition [35,40,41] and also plays a role in mood disorders [42].”
Tremella fuciformis Berk alleviates depression by inhibiting NF-κB signaling in mice
Liu, S., Zhang, H., Chen, Y., Liu, Y., & Wang, C. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106779 · Cited by 3
Chu, H., Sun, N., Tang, Q., Yu, X. L., Li, L., & Hong-sheng, C. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119960 · Cited by 4
Luo, S., Qi, Z., Wu, F., Tao, D., Huang, S., Shi, C., Yang, C., Shi, Y., & Luo, Y. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110508 · Cited by 3
“These symptoms are associated with impairments in brain regions that regulate emotions, including the hippocampus, prefrontal cortex, and nucleus accumbens (Duman and Aghajanian, 2012).”
Zhou, J.-X., Liu, X.-B., Zheng, Z.-Y., Ji, M.-X., & Wei, K. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119607 · Cited by 3
Chen, Y., Yang, S., Shi, H., Cui, J., & Zhu, L. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70408 · Cited by 5
“However, pharmacological treatments often come with significant limitations, including strong dependency, notable side effects, and in some cases, treatment-resistant depression (Carvalho et al. 2016; Duman and Aghajanian 2012).”
Investigating acupuncture therapy in depression: mechanisms of synaptic plasticity regulation
Si, Y., Ma, W., Zhang, Q., Zhang, Y., An, J., Zhang, M., Fu, Y., Yu, Y., Zhang, H., Fang, Y., et al. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.06.005 · Cited by 6
Cathepsin B deficiency disrupts cortical development via PEG3, leading to depression-like behavior
Xie, Z., Yang, Q., Lan, F., Kong, W., Zhao, S., Sun, J., Yan, Y., Quan, Z., Bai, Z., Qing, H., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08508-8 · Cited by 5
“Changes in both mPFC architecture and the function of mPFC neurons have been reported in depression, including neuronal volume reduction 63 , synapse loss 64 , altered synaptic transmission 65 , and downstream structures 66 .”
The Acute and Chronic Effects of Ketamine as Revealed by Noninvasive Brain Imaging
Li, M., & Walter, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00064-9 · Cited by 3
A Review on Diagnostic Proteomics of Depression
Samad, N. (2017) · MOJ Proteomics & Bioinformatics · doi:10.15406/mojpb.2017.06.00187 · Cited by 2
“Synaptic plasticity is a well-known mechanism in learning and memory [16] and dysfunction of synaptic plasticity with neuronal atropy and cell death contribute to pathophysiology of depression [17,18].”
BackgroundNeuroprotective roles of neurotrophic growth factors in mood disorders
Jiang, C. S., & Salton, S. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814037-6.00010-0 · Cited by 4
Neurochemical Signaling in Depression: Impact of Target-Based Pharmaceuticals
Sharma, B., & Khushboo (2022) · Current Drug Therapy · doi:10.2174/1574885517666220817122840 · Cited by 4
Wang, L., Chen, X., Gu, X., Smedt, H. D., Popova, V., Fu, D., Canuso, C. M., Drevets, W. C., & Chen, G. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s417027 · Cited by 6
“18,19 The mechanisms of Ketamine/Esketamine have also been shown to go beyond NMDA antagonism and may act as multimodal agent in regulation of tonic membrane influx of Ca 2+ and Na+, synaptic protein translation, neuroplasticity, and modulation of glycogen synthase kinase-3β.”
Artificial intelligence–based depression detection using EEG signals
Tokmak, F., & Subaşı, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22308-2.00007-x · Cited by 4
Tao, L., Li, X., Tu, X., Liu, R., Xu, J., Lv, Y., & Yao, Y. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115139 · Cited by 4
Bastawy, E. M., Eraslan, I. M., Voglsanger, L. M., Suphioglu, C., Walker, A. J., Dean, O. M., Read, J. L., Ziemann, M., & Smith, C. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137391 · Cited by 4
Functional excitation-inhibition ratio for social anxiety analysis and severity assessment
Chu, L. H., Chau, C. Q., Kamel, N., Ha, H., & Yahya, N. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1461290 · Cited by 5
“The ratio ’ s sensitivity is con fi rmed by consistent fi ndings across neuroimaging and electrophysiological studies (27).”
BackgroundTsybko, A. S., Ilchibaeva, T. V., & Naumenko, V. S. (2015) · Russian Journal of Genetics Applied Research · doi:10.1134/s2079059715040152 · Cited by 3
“The idea that the efficacy of antidepressants signif icantly depends on increased neurogenesis and neu ronal plasticity (Duman and Aghajanian, 2012) has promoted intense studies on neurotrophic factors as a target for antidepressant therapy.”
BackgroundMapping of Nervous System Diseases via MicroRNAs
(2016) · CRC Press eBooks · doi:10.1201/b19229 · Cited by 3
Depression and antidepressant action—from molecules to networks
Rantamäki, T., & Yalçın, İ. (2019) · Cell and Tissue Research · doi:10.1007/s00441-019-03042-6 · Cited by 4
Ketamine restores escape behavior by re-engaging dopamine systems to drive cortical spinogenesisPreprint
Wu, M., Minkowicz, S., Dumrongprechachan, V., Hamilton, P. J., Xiao, L., & Kozorovitskiy, Y. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.11.987818 · Cited by 3
Shen, J., Lin, L., Liao, L., Liang, W., Yang, X., Lin, K., Ke, L. W., Zhang, L., Kang, J., Ding, S., et al. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135244 · Cited by 3
RetractedDahan, A., & Henthorn, T. K. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.991569 · Cited by 4
The role of immunity in comorbid pain and depression
Ciaramella, A., & Carli, G. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00168 · Cited by 4
Chuang, H.-W., Huang, C., Chen, K.-T., Kuo, Y.-Y., Ren, J.-H., Wang, T.-Y., Tsai, M., Chen, P.-T., & Wei, I. (2024) · Psychiatry Investigation · doi:10.30773/pi.2024.0238 · Cited by 183
Wang, D., Fukuda, T., Wu, T., Xu, X., Isaji, T., & Gu, J. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108230 · Cited by 3
“The Iba1 antibody (catalog no. 019 – 19741) was purchased from FUJIFILM Wako Pure Chemical Corporation, and the anti-PSD-95 antibody (catalog no.”
InfluentialEffects of Qingyangshen glycosides on neuroplasticity in a mouse model of social defeat
Wang, J., Chen, W., Zhu, Q., Liu, Y., Zheng, K., Liu, D., & Zeng, G. (2025) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12499 · Cited by 3
“10,11 SYN and PSD-95 are thought to play critical roles in neuroplasticity.”
Neuromodulation in Neural Circuits: Neurotransmitters and Synaptic Plasticity
Chaudhary, U. (2025) · Springer eBooks · doi:10.1007/978-3-031-76081-5_6 · Cited by 5
Lu, S., Shen, J.-D., Jin, X., Zhang, C., Wang, B., Liu, X., Bai, M., Xu, E., Yan, X., & Li, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1577676 · Cited by 7
“A growing body of evidence demonstrates that depression is fundamentally associated with synaptic dysfunction (Duman and Aghajanian, 2012; Rantamäki and Kohtala, 2020).”
Ram, D. (2025) · NeuroPharmac Journal · doi:10.37881/1.1012 · Cited by 2
Cholesterol, Cognition, and Controversy: A Case of Mood Disturbance on Repatha
Conte, M., Mao, B., Tahir, S., Rodriguez, A., & Hussain, S. T. (2025) · Cureus · doi:10.7759/cureus.87165 · Cited by 2
“Although a reduction in dendritic spine length observed in mice differs from a reduction in dendritic spine number reported in human functional imaging studies [8,14], both findings suggest structural alteration of synaptic integrity.”
Gene expression signatures of response to fluoxetine treatment: systematic review and meta-analyses
Cooper, D. G., Cowden, J. P., Vo, P., Stanley, P. E., Karbowski, J. T., Gaertig, V. S., Lukan, C. J., Worthington, A., & Class, C. A. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03118-6 · Cited by 3
Du, Z., Chu, C., Shi, W., Luo, N., Lu, Y., Wang, H., Zhao, B., Xiong, H., Yang, Z., & Jiang, T. (2025) · Nature Communications · doi:10.1038/s41467-025-63204-9 · Cited by 3
“The aberrant expression of ligands or receptors can alter interregional communication, which in turn can lead to cognitive impairment and neuro-logicaldisorders 11,25 – 27 .”
Li, X., Hua, Y., Li, H., Feng, Y., Wu, C., Hu, X., Zhang, Z., Zhou, X., & Dong, X. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.09.037 · Cited by 2
Filipović, D., & Turck, C. W. (2025) · Biomolecules · doi:10.3390/biom15101358 · Cited by 4
“The resulting shift in energy allocation may drive the dendritic atrophy and decreased synaptic connectivity observed in depression, thereby creating a cycle in which impaired energy metabolism further exacerbates synaptic dysfunction [64,65].”
Xue, S., Chen, N., Liu, Y., Cai, X., Shen, Y., Yue, H., & Yan, W. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.140095 · Cited by 3
From stress to Alzheimer’s: A circuit-based framework for prefrontal cognitive dysfunction
Yi, J. H. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138424 · Cited by 3
Li, P., & Gao, Y. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1651207 · Cited by 4
Alatawi, Z. (2025) · Developmental Neurobiology · doi:10.1002/dneu.23014 · Cited by 2
“Increased synaptic plasticity and enhanced connectivity have been observed following this effect (Duman and Aghajanian 2012; Akinfiresoye and Tizabi 2013).”
Xie, Z., Chen, M., Yi, W., Wang, S., Deng, D., An, L., Zhao, J., Bai, S., Yang, L., Shi, Y., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120841 · Cited by 2
Zhang, Y., Li, Y., Wang, J., Song, Y., Dong, Q., Cong, L., Wang, Y., Hou, T., Han, X., Du, Y., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.121040 · Cited by 2
Major depressive disorder: susceptibility, underlying mechanisms, and emerging therapies
Onisiforou, A., Koumas, M., & Zanos, P. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.12.003 · Cited by 2
Le, G. H., & McIntyre, R. S. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2619757 · Cited by 4
“● Selective dampening of NR2C/D-mediated tonic currents may underlie rapid and sustained antidepressant effects of ketamine, esketa-mine, and dextromethorphan. and activity-regulated cytoskeleton-associated protein (Arc) [34,63,64].”
Zhang, M., & Jin, W.-L. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218351 · Cited by 4
Synaptic density in the hippocampus of depressed patients: A quantitative electron microscopic study
Sebők-Tornai, A., Csabai, D., Szocsics, P., Gombás, P., Cobb, J. A., Mahajan, G., Stockmeier, C. A., & Czéh, B. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111661 · Cited by 2
“…and one prominent theory proposes that depression is caused by dysfunctional synaptic plasticity, eventually resulting in synaptic loss and consequently in disrupted emotion circuitry (Duman and Aghajanian, 2012; Duman et al., 2016; Sanacora et al., 2022; Fries et al., 2023; Thompson, 2023).”
Fortea, L., Rivas‐Fernández, M. Á., Solanes, A., King, S., Nabulsi, L., Alda, M., Alexander, N., Bauer, J., Benedetti, F., Borgers, T., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03536-0 · Cited by 2
“…diffuse monoaminergic projections of serotonergic and noradrenergic systems [57, 58], and with evidence that chronic SSRI/SNRI treatment enhances neuroplasticity through BDNF – TrkB signaling, synaptic remodeling, and network-level normalization of fronto-cingulate and limbic circuits [59 – 62].”
Trajectories of late-life depression: insights from molecular imaging
Holmes, S. E., & Smith, G. S. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02340-2 · Cited by 2
Metadata
- Authors
- Duman, R. S., & Aghajanian, G. K.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- ORCID
- Duman, Ronald S.
- Venue
- Science
- Published
- 2012-10-05
- Volume
- 338
- Issue
- 6103
- Pages
- 68-72
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4424898
- OpenAlex
- W2157504436
- Cited by
- 1,651
- References
- 57
- Citations by year
- 2026: 176 · 2025: 175 · 2024: 132 · 2023: 138 · 2022: 127 · 2021: 161 · 2020: 125 · 2019: 86 · 2018: 88 · 2017: 93 · 2016: 89 · 2015: 106 · 2014: 78 · 2013: 71 · 2012: 4
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH093897)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, synaptic dysfunction, synaptogenesis, ketamine, NMDA receptor antagonists, antidepressant resistance, chronic stress, prefrontal cortex, hippocampus, mood regulation, rapid antidepressant response, therapeutic target
- MeSH terms
- Animals, Antidepressive Agents, Atrophy, Behavior, Major Depressive Disorder, Homeostasis, Humans, Neurons, Stress, Psychological, Synapses, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.